Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension

American Journal of Hypertension

Volumn 10, Issue 12 I, 1997, Pages 1349-1355

  Dominguez, Ligia J ^a   Barbagallo, Mario ^b   Jacober, Scott J ^a   Jacobs, David B ^c   Sowers, James R ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Insulin receptor; Tyrosine kinase; Blockers

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN RECEPTOR; IODINE 125; PROTEIN TYROSINE KINASE;

ADRENERGIC RECEPTOR BLOCKING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING;

EID: 0031417263     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00320-8     Document Type: Article

References (37)

1. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease and nephropathy an update . Hypertension. 26:1995;869-879.
2. Report on hypertension and diabetes. Hypertension. 23:1994;145-158.
3. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med. 317:1987;3500-3507.
4. Shen DC, Shien SM, Fuh MT, et al. Resistance to insulin-stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab. 66:1988;580-583.
5. Barbagallo M, Resnick LM: Calcium and Magnesium in the regulation of smooth muscle function and blood pressure. The ionic hypothesis of cardiovascular and metabolic diseases and vascular aging, in JR Sowers (ed): Endocrinology of the Vasculature. Humana Press, Totowa, NJ, 1996, pp 283-300.
6. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism. 39:1990;167-174.
7. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med. 320:1989;702-706.
8. Julius S, Jamerson K, Mejia A, et al. The association of borderline hypertension with target organ changes and higher coronary risk Tecumseh Blood Pressure Study . JAMA. 264:1990;354-358.
9. Lithell H. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care. 14:1991;203-209.
10. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease Part 2. Short-term reduction in blood pressure: overview of randomized drug trials in their epidemiologic context . Lancet. 335:1990;827-838.
11. Black HR. The coronary artery paradox the role of hyperinsulinemia and insulin resistance and implications for therapy . J Cardiovasc Pharmacol. 15:1990;S26-S38.
12. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care. 14:1991;39-47.
13. Pollare T, Lithell HO, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 321:1989;868-873.
14. Lithell H. Metabolic effects of antihypertensive drugs interacting with the sympathetic nervous system. Eur Heart J. 13:1992;53-57.
15. Hoes AW, Grobbee DE, Lubsen J, et al. Diuretics, β-blockers and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med. 123:1995;481-487.
16. Warram J, Laffel LM, Valsania P, Christlieb AR, Krolewski AS. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med. 151:1991;1350-1356.
17. Frishman WH. Beta adrenergic receptor blockers adverse effects and drug interactions . Hypertension. 11:1988;21-29.
18. Houston MC. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J. 115:1988;640-656.
19. Heinemann L, Heise T, Ampudia J, et al. Four week administration of an ACE inhibitor and a cardioselective β-blocker in healthy volunteers no influence on insulin sensitivity . Eur J Clin Invest. 25:1995;595-600.
20. Böhlen LM, Courten M, Hafezi F, et al. Insulin sensitivity and atrial natriuretic factor during β-receptor modulation with celiprolol in normal subjects. J Cardiovasc Pharmacol. 23:1994;877-883.
21. Agino H, Shishii K, Yokono K, et al. Enzyme-linked immunosorbent assay methods for human autophosphorylated insulin receptor applicability to insulin-resistant states . Diabetes. 43:1994;274-280.
22. Comi RJ, Grunberger G, Gorden P. Relationship of insulin binding and insulin-stimulated tyrosine kinase activity is altered in type II diabetes. J Clin Invest. 79:1987;453-462.
23. Dominguez LJ, Weinberger MH, Cefalu WT, et al. Doxazosin lowers blood pressure and improves insulin responses to a glucose load with no changes in tyrosine kinase activity or insulin binding. Am J Hypertens. 8:1995;528-532.
24. Friedewald WT, Levy RT, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of a centrifuge. Clin Chem. 18:1972;449-502.
25. Gambhir K, Archer J, Bradley C. Characteristics of human erythrocyte insulin receptors. Diabetes. 27:1978;701-708.
26. Sowers JR, Jacobs DB, Simpson L, et al. Erythrocyte insulin and insulin-like growth factor-I receptor tyrosine kinase activity in hypertension in pregnancy. Metabolism. 44:1995;1308-1313.
27. The fifth report of Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 153:1993;154-183.
28. Yusuf S, Lessem J, Jha P, Lonn E. Primary and secondary prevention of myocardial infarction and strokes an update of randomly allocated, controlled trials . J Hypertens. 11:1993;S61-S73.
29. Weber MA, Laragh JH. Steps forward and steps backwards the Joint National Committee Fifth Report . Arch Intern Med. 153:1993;149-152.
30. William-Olsson T, Fellenius E, Björntorp P, Smith U. Differences in metabolic response to beta-adrenergic stimulation after propranolol or metoprolol administration. Acta Med Scand. 205:1979;201-206.
31. Haffner CA, Horton RC, Lewis HM, et al. A metabolic assessment of the beta 1 selectivity of bisoprolol. J Human Hypertens. 6:1992;397-400.
32. Donnelly R. Angiotensin-converting enzyme inhibitors and insulin sensitivity metabolic effects in hypertension, diabetes and heart failure . J Cardiovasc Pharmacol. 20:(suppl 11):1992;S38-S44.
33. Kahn CR, White MF. The insulin receptor and the molecular mechanism of insulin action. J Clin Invest. 82:1988;1151-1156.
34. Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev. 16:1988;117-142.
35. Kahn CR. Insulin action, diabetogenes and the cause of type II diabetes. Diabetes. 43:1994;1066-1084.
36. Rossetti L, DeFronzo RA, Gherzi R, et al. Effect of metformin treatment on insulin action in diabetic rats in vivo and in vitro correlations . Metabolism. 39:1990;425-435.
37. Nyomba BL, Ossowski VM, Saad MF, et al. Tyrosine kinase activity of skeletal muscle during insulin infusion in humans. J Clin Endocrinol Metab. 75:1992;218-223.